Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

REsponse Adapted Combination Therapy Approaches for High-Risk Multiple Myeloma (REACH)

NCT05497804 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT05497804
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05497804 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
REsponse Adapted Combination Therapy Approaches for High-Risk Multiple Myeloma (REACH)
Lead sponsor
Mayo Clinic
Phase
Phase 2
Overall status
Active, not recruiting
Start date
September 22, 2022
Completion date
September 4, 2028
Enrollment
17 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

iss stage iii plasma cell myeloma, multiple myeloma